Veracyte (VCYT)
Develops molecular tests that guide cancer diagnosis, treatment, and recurrence monitoring.
$43.36
After hours0.00 (0.00%)
At close$43.36(+4.43%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90 | 98 | 97 | 114 | 116 | 119 | 114 | 130 | 132 | 141 | 139 | 150 |
| Cost of revenue | 28 | 29 | 34 | 37 | 37 | 40 | 35 | 40 | 41 | 36 | 38 | 42 |
| Gross profit | 62 | 69 | 62 | 78 | 79 | 79 | 80 | 90 | 91 | 105 | 101 | 109 |
| 94 | 104 | 67 | 73 | 67 | 75 | 77 | 95 | 68 | 79 | 77 | 86 | |
| Research & development | 13 | 19 | 16 | 16 | 18 | 19 | 18 | 16 | 16 | 21 | 27 | 29 |
| 41 | 48 | 49 | 54 | 47 | 55 | 59 | 57 | 51 | 44 | 51 | 56 | |
| Selling & marketing | 24 | 7 | 6 | 7 | 7 | 8 | 7 | 43 | 7 | 43 | 27 | 28 |
| General & administrative | 16 | 41 | 43 | 47 | 40 | 47 | 52 | 14 | 43 | 1 | 24 | 27 |
| Other expenses | 40 | 37 | 2 | 3 | 2 | 0 | 0 | 22 | 2 | 14 | −1 | 0 |
| Operating income | −32 | −36 | −5 | 5 | 12 | 4 | 3 | −5 | 23 | 26 | 24 | 23 |
| 2 | 5 | 3 | 3 | 5 | −1 | 5 | 7 | −4 | 15 | 6 | −4 | |
| Interest income | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 4 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | −2 | −5 | −1 | −3 | −5 | 1 | 2 | −7 | 4 | −15 | −6 | 4 |
| Income before tax | −30 | −30 | −2 | 7 | 17 | 3 | 7 | 1 | 19 | 41 | 30 | 19 |
| Income tax expense | 0 | −2 | 0 | 2 | 2 | −2 | 0 | 2 | 0 | −1 | 1 | −6 |
| Net income from continuing operations | −30 | −28 | −2 | 6 | 15 | 5 | 7 | −1 | 19 | 41 | 29 | 25 |
| Net income | −30 | −28 | −2 | 6 | 15 | 5 | 7 | −1 | 19 | 41 | 29 | 25 |
| EPS, basic | −$0.41 | −$0.39 | −$0.02 | $0.07 | $0.20 | $0.07 | $0.09 | −$0.01 | $0.24 | $0.52 | $0.36 | $0.32 |
| EPS, diluted | −$0.41 | −$0.39 | −$0.02 | $0.07 | $0.19 | $0.06 | $0.09 | −$0.01 | $0.24 | $0.50 | $0.35 | $0.31 |
| Weighted average shares, basic | 73 | 73 | 75 | 77 | 77 | 78 | 78 | 78 | 79 | 79 | 80 | 80 |
| Weighted average shares, diluted | 73 | 73 | 75 | 77 | 78 | 80 | 80 | 80 | 80 | 81 | 81 | 82 |
| EBITDA | −22 | −24 | 2 | 13 | 23 | 10 | 7 | 7 | 24 | 46 | 35 | 24 |
| Depreciation & amortization | 7 | 6 | 6 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 5 | 5 |
| EBIT | −30 | −30 | −4 | 7 | 17 | 3 | 1 | 1 | 19 | 41 | 30 | 19 |